Abraxane

(Nab-paclitaxel)

ApprovedSmall molecule

Nab-paclitaxel is a cancer medication used to treat several types of cancer including breast cancer, lung cancer, and pancreatic cancer by stopping cancer cells from dividing and growing.[2] Abraxane is currently approved and in use across 73 indications[4].[1]

Abraxane is one of 1062 small molecule programs targeting Pancreatic Carcinoma. It is currently in Approved.

Indications

613

Total Trials

Active Trials

1,061

Competitors

Pipeline

Status by Indication[4][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

Cervical AdenocarcinomaActive, not recruiting

Gastric AdenocarcinomaActive, not recruiting

Desmoplastic Small Round Cell TumorActive, not recruiting

Pancreatic CarcinomaPhase 1

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Esophageal CarcinomaPhase 2

Active, not recruiting

Nasopharyngeal CarcinomaPhase 1

Active, not recruiting

Lung CancerPhase 3

Active, not recruiting

Esophageal CancerPhase 2

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

Cervical AdenocarcinomaPhase 2

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Active, not recruiting

Desmoplastic Small Round Cell TumorPhase 2

Active, not recruiting

Showing 10 of 73 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Approved

89 2

Halaven

Eisai

Preclinical

38 3

Trodelvy

Gilead

Preclinical

37 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Avastin

Voltaren

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Breast Cancer

NCT03734029

Phase 2Active, not recruiting

Pancreatic Cancer

NCT03816163

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT04253964

Phase 2Recruiting

Pancreatic Cancer

NCT03492671

Phase 3Recruiting

Nab-Paclitaxel

NCT03257033

Q4 2026

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05635708

Clinical

Trials by Indication[1]

Pancreatic Cancer41 trials

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Unknown status·—·Phase 1·NCT03703063·30 enrolled

Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients

Completed·AAIO-Studien-gGmbH·Phase 4·NCT02812992·32 enrolled

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT02514031·17 enrolled

Show 38 more trials

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Completed·EEmory University·Phase 2·NCT04524702·10 enrolled

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06897644·340 enrolled

Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer

Recruiting·LLoma Linda University·Phase 2·NCT03492671·30 enrolled

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04581876·120 enrolled

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02620800·12 enrolled

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT04216758·300 enrolled

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Completed·HHerlev Hospital·Phase 1/2·NCT04247165·55 enrolled

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT06199466·4 enrolled

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07283705·60 enrolled

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Unknown status·—·Phase 2·NCT04902261·140 enrolled

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07079228·602 enrolled

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Terminated·NNewLink Genetics Corporation·Phase 3·NCT01836432·302 enrolled

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 2·NCT03816163·393 enrolled

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Unknown status·FFudan University·Phase 3·NCT02506842·300 enrolled

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Completed·OOsaka Medical Center for Cancer and Cardiovascular Diseases·Phase 1·NCT02272738·54 enrolled

Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer

Unknown status·UUS Oncology Research·Phase 1·NCT01934634·24 enrolled

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer

Recruiting·FFudan University·Phase 2·NCT06196788·30 enrolled

Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer

Terminated·—·Phase 1·NCT03520790·36 enrolled

Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02017015·83 enrolled

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT02005315·30 enrolled

Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer

Recruiting·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT06576115·30 enrolled

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01632306·13 enrolled

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Active, not recruiting·UUnknown Sponsor·Phase 1·NCT03252808·36 enrolled

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Unknown status·FFudan University·Phase 3·NCT04835064·600 enrolled

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Completed·GGWT-TUD GmbH·Phase 1/2·NCT04257448·75 enrolled

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1/2·NCT06662669·120 enrolled

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06080854·108 enrolled

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Terminated·—·Phase 1·NCT03519308·3 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06528093·8 enrolled

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Unknown status·—·Phase 1/2·NCT03989310·50 enrolled

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 1/2·NCT01647828·217 enrolled

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

Completed·—·Phase 1·NCT02550327·20 enrolled

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT05562297·50 enrolled

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03336216·205 enrolled

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

Active, not recruiting·QQueen Mary University of London·Phase 2·NCT04241276·170 enrolled

Breast Cancer35 trials

Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06964906·140 enrolled

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05840211·654 enrolled

Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00629499·63 enrolled

Show 32 more trials

Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT01565499·83 enrolled

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

Completed·GGBG Forschungs GmbH·Phase 3·NCT01583426·1,229 enrolled

Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06802757·72 enrolled

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Recruiting·FFudan University·Phase 2·NCT06387628·74 enrolled

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer

Completed·UUniversity of Utah·Phase 1/2·NCT00748553·30 enrolled

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01036087·47 enrolled

Schedules of Nab-Paclitaxel in Metastatic Breast Cancer

Completed·EETOP IBCSG Partners Foundation·Phase 2·NCT01746225·258 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04895358·340 enrolled

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 1/2·NCT06140576·58 enrolled

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

Completed·SSorrento Therapeutics, Inc.·N/A·NCT02064829·111 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 3·NCT03734029·557 enrolled

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Active, not recruiting·DDualityBio Inc.·Phase 3·NCT06018337·541 enrolled

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT05633914·90 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer

Unknown status·BBarwon Health·Phase 2·NCT01830244·60 enrolled

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Completed·NNektar Therapeutics·Phase 3·NCT02915744·178 enrolled

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

Completed·WWest German Study Group·Phase 2·NCT01815242·336 enrolled

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03175666

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer

Withdrawn·MMedSIR·Phase 1/2·NCT04826016

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated·IImmunityBio, Inc.·Phase 1/2·NCT03387085·9 enrolled

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT02685059·174 enrolled

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Unknown status·FFudan University·Phase 2·NCT04734262·98 enrolled

Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer

Completed·NNorthwestern University·Phase 1·NCT00983424·14 enrolled

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04355858·319 enrolled

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT02019277·50 enrolled

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00944047·32 enrolled

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00392392·29 enrolled

Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07340398·200 enrolled

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Active, not recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT04398914·216 enrolled

A Study for the Neoadjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420454·1,576 enrolled

EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer

Completed·FFondazione Sandro Pitigliani·Phase 2·NCT02783222·160 enrolled

Nab-paclitaxel11 trials

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Completed· GSK logo

GSK·Phase 1·NCT01192165·169 enrolled

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04015778·48 enrolled

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

Recruiting·RRenovoRx·Phase 3·NCT03257033·190 enrolled

Show 8 more trials

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06632405·60 enrolled

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Completed·IInstitut fuer Frauengesundheit·Phase 2·NCT03289819·53 enrolled

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Unknown status·FFudan University·Phase 2·NCT04537286·90 enrolled

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Completed·—·Phase 2·NCT02716038·39 enrolled

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07125547·35 enrolled

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT04725448·27 enrolled

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02289456·40 enrolled

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT07233252·35 enrolled

Pancreatic Adenocarcinoma10 trials

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma

Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 1/2·NCT02504333·168 enrolled

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Completed·CCancer Insight, LLC·Phase 1·NCT04787991·45 enrolled

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01431794·23 enrolled

Show 7 more trials

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Unknown status·NNovoCure GmbH·Phase 1/2·NCT01971281·40 enrolled

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02109445·3 enrolled

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Completed·NNovoCure GmbH·Phase 3·NCT03377491·571 enrolled

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Completed·IIRCCS San Raffaele·Phase 1/2·NCT01730222·137 enrolled

Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology

Unknown status·—·Phase 1·NCT03703089·21 enrolled

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Recruiting·AAshish Manne·Phase 2·NCT05624918·38 enrolled

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT05825066·64 enrolled

Triple-Negative Breast Cancer9 trials

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Completed·—·Phase 2·NCT03121352·30 enrolled

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06279364·524 enrolled

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05227664·120 enrolled

Show 6 more trials

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT04148911·184 enrolled

Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment

Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT04085276·531 enrolled

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05422794·57 enrolled

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT03800836·139 enrolled

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

Unknown status·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT03961698·91 enrolled

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05491694·20 enrolled

56 more indications

Non-Small Cell Lung Cancer8 trials

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT04253964·105 enrolled

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02775435·559 enrolled

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06692738·880 enrolled

Show 5 more trials

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04956692·531 enrolled

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03574649

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed· Roche logo

Roche·Phase 3·NCT03456063·453 enrolled

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Completed·LLiza Villaruz, MD·Phase 2·NCT02730247·7 enrolled

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active, not recruiting· BeiGene logo

BeiGene·Phase 2·NCT05635708·400 enrolled

Pancreatic Ductal Adenocarcinoma8 trials

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 1/2·NCT06904378·61 enrolled

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting·NNovoCure GmbH·Phase 2·NCT06390059·84 enrolled

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

Show 5 more trials

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 3·NCT02715804·492 enrolled

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·GGerman Cancer Research Center·Phase 1·NCT05494866·6 enrolled

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·CCorcept Therapeutics·Phase 3·NCT04329949·43 enrolled

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruiting· Revolution Medicines logo

Revolution Medicines·Phase 3·NCT06625320·501 enrolled

Advanced Solid Tumors6 trials

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Completed·FFaeth Therapeutics·Phase 1·NCT05300048·34 enrolled

Show 3 more trials

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Recruiting·TTCRCure Biopharma Ltd.·Phase 1·NCT05881525·18 enrolled

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03396445·182 enrolled

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Completed·EEucure (Beijing) Biopharma Co., Ltd·Phase 1/2·NCT04481009·26 enrolled

Chemotherapy4 trials

CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)

Recruiting·JJohn Lenehan·Phase 1·NCT06393400·20 enrolled

A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Unknown status·Ee-Therapeutics PLC·Phase 1·NCT02423239·112 enrolled

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Recruiting·AAHS Cancer Control Alberta·Phase 2·NCT05451043·62 enrolled

Show 1 more trial

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT07024615·25 enrolled

Gastric Cancer4 trials

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04572542·46 enrolled

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Recruiting·SShandong Tumor Hospital·Phase 2·NCT07320586·40 enrolled

Show 1 more trial

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

Completed·HHellenic Oncology Research Group·Phase 2·NCT02251951·39 enrolled

Head and Neck Squamous Cell Carcinoma4 trials

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03174275·39 enrolled

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed· AbbVie logo

AbbVie·Phase 1·NCT04196283·30 enrolled

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03169764

Show 1 more trial

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Unknown status·XXiang Lu·Phase 2·NCT06235918·30 enrolled

Immunotherapy2 trials

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06300424·32 enrolled

Second-line Immunotherapy for ES-SCLC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT06853678·30 enrolled

Non-squamous NSCLC2 trials

Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.

Withdrawn·WWest Virginia University·Phase 2·NCT02405910

Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC

Unknown status·SShanghai Chest Hospital·Phase 2·NCT04405674·120 enrolled

Cancer2 trials

Study of ORIC-101 in Combination With Anticancer Therapy

Terminated·OORIC Pharmaceuticals·Phase 1·NCT03928314·83 enrolled

Safety Study of SEA-CD40 in Cancer Patients

Terminated· Pfizer logo

Pfizer·Phase 1·NCT02376699·159 enrolled

Metastatic Melanoma2 trials

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00833807·30 enrolled

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00738361·4 enrolled

Lung Cancer2 trials

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Terminated·WWuhan University·Phase 2·NCT03802058·24 enrolled

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Completed· BeiGene logo

BeiGene·Phase 3·NCT03594747·360 enrolled

Small Cell Lung Cancer2 trials

The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer

Unknown status·TTongji University·Phase 2·NCT02262897·40 enrolled

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT03262948·388 enrolled

Bladder Carcinoma2 trials

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04730219·48 enrolled

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04730232·63 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Recruiting·SSichuan University·Phase 2·NCT06446726·30 enrolled

Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma

Recruiting·RRuijin Hospital·Phase 2·NCT06122493·48 enrolled

Pancreas Cancer2 trials

Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine For The First Line Treatment of Pancreas Cancer

Completed·HHacettepe University·Phase 2·NCT03807999·125 enrolled

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Withdrawn·DDevalingam Mahalingam·Phase 1/2·NCT05251038

First Line Therapy2 trials

First-line Therapy in Metastatic PDAC

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT03487016·270 enrolled

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Active, not recruiting·BBiotheus Inc.·Phase 1/2·NCT05918133·42 enrolled

Locally Advanced1 trial

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Recruiting·TTang-Du Hospital·Phase 2·NCT07353723·10 enrolled

Gastrointestinal1 trial

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Recruiting· Revolution Medicines logo

Revolution Medicines·Phase 1/2·NCT06445062·1,130 enrolled

Radiotherapy1 trial

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06472037·30 enrolled

Neuroendocrine Carcinoma1 trial

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas

Unknown status·BBarwon Health·Phase 2·NCT02215447·4 enrolled

Advanced Solid Malignancies1 trial

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Completed·WWashington University School of Medicine·Phase 1·NCT01677559·34 enrolled

Metastatic Solid Tumors1 trial

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Urothelial Cancer1 trial

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197571

Refractory Sarcoma1 trial

Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02945800·59 enrolled

Combination Therapy1 trial

IN10018 Combination Therapy in Previously-treated Solid Tumors

Not yet recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05982522·72 enrolled

Advanced Cancer1 trial

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Advanced/Metastatic Cancer1 trial

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02857270·210 enrolled

Efficacy1 trial

Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC

Active, not recruiting·PPeptomyc S.L.·Phase 1·NCT06059001·26 enrolled

Elderly Patients1 trial

Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC

Withdrawn·SShirish Gadgeel·Phase 2·NCT04754815

Adenocarcinoma1 trial

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04140318·60 enrolled

Malignant Mesothelioma1 trial

Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02798536·21 enrolled

Prostate Cancer1 trial

A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1/2·NCT04148885·44 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Withdrawn·EEmory University·Phase 2·NCT05514912

Advanced Urothelial Cancer1 trial

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02033993·199 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT06041035·115 enrolled

PD-L1 Positive1 trial

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07040644·150 enrolled

Esophageal Cancer1 trial

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT02317991·65 enrolled

Endometrial Cancer1 trial

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06132958·710 enrolled

Radiation Therapy1 trial

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Terminated·VVanderbilt-Ingram Cancer Center·Phase 1/2·NCT00544648·13 enrolled

Monotherapy1 trial

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Terminated· Amgen logo

Amgen·Phase 1·NCT05267470·74 enrolled

Malignant Tumors1 trial

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Completed·CCantargia AB·Phase 1/2·NCT03267316·167 enrolled

Metastatic1 trial

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01893801·25 enrolled

Treatment1 trial

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Advanced Cancers1 trial

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Completed·TTrishula Therapeutics, Inc.·Phase 1·NCT03884556·56 enrolled

Cervical Adenocarcinoma1 trial

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06654011·25 enrolled

Merkel Cell Carcinoma1 trial

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03167164

Peritoneal Carcinomatosis1 trial

PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis

Active, not recruiting·UUniversity Hospital, Geneva·Phase 1·NCT04000906·18 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT06561685·340 enrolled

Bile Duct Cancer1 trial

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Completed·EEmory University·Phase 2·NCT03579771·30 enrolled

Neoadjuvant Immunotherapy1 trial

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT05800340·30 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Terminated·NNektar Therapeutics·Phase 1/2·NCT03138889·162 enrolled

Refractory Solid Tumors1 trial

Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Completed·EEmory University·Phase 1·NCT03507491·24 enrolled

Biliary Tract Cancer1 trial

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

Unknown status·IIstituto Clinico Humanitas·Phase 1/2·NCT03943043·85 enrolled

Infusion1 trial

Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC

Withdrawn·LLisata Therapeutics, Inc.·Phase 1/2·NCT06592664

Efficacy and Safety1 trial

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Terminated· Novartis logo

Novartis·Phase 3·NCT03631199·673 enrolled

Sources

References

[1]
ClinicalTrials.gov — 613 trial records for Nab-paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Abraxane drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Nab-paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Nab-paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb

Abraxane

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Pancreatic Cancer41 trials

Breast Cancer35 trials

Nab-paclitaxel11 trials

Pancreatic Adenocarcinoma10 trials

Triple-Negative Breast Cancer9 trials

Non-Small Cell Lung Cancer8 trials

Pancreatic Ductal Adenocarcinoma8 trials

Advanced Solid Tumors6 trials

Chemotherapy4 trials

Gastric Cancer4 trials

Head and Neck Squamous Cell Carcinoma4 trials

Immunotherapy2 trials

Non-squamous NSCLC2 trials

Cancer2 trials

Metastatic Melanoma2 trials

Lung Cancer2 trials

Small Cell Lung Cancer2 trials

Bladder Carcinoma2 trials

Esophageal Squamous Cell Carcinoma2 trials

Pancreas Cancer2 trials

First Line Therapy2 trials

Locally Advanced1 trial

Gastrointestinal1 trial

Radiotherapy1 trial

Neuroendocrine Carcinoma1 trial

Advanced Solid Malignancies1 trial

Metastatic Solid Tumors1 trial

Urothelial Cancer1 trial

Refractory Sarcoma1 trial

Combination Therapy1 trial

Advanced Cancer1 trial

Advanced/Metastatic Cancer1 trial

Efficacy1 trial

Elderly Patients1 trial

Adenocarcinoma1 trial

Malignant Mesothelioma1 trial

Prostate Cancer1 trial

Intrahepatic Cholangiocarcinoma1 trial

Advanced Urothelial Cancer1 trial

Transplantation1 trial

Patients With Advanced Solid Tumors1 trial

PD-L1 Positive1 trial

Esophageal Cancer1 trial

Endometrial Cancer1 trial

Radiation Therapy1 trial

Monotherapy1 trial

Malignant Tumors1 trial

Metastatic1 trial

Treatment1 trial

Advanced Cancers1 trial

Cervical Adenocarcinoma1 trial

Merkel Cell Carcinoma1 trial

Peritoneal Carcinomatosis1 trial

Advanced or Metastatic Solid Tumors1 trial

Bile Duct Cancer1 trial

Neoadjuvant Immunotherapy1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Refractory Solid Tumors1 trial

Biliary Tract Cancer1 trial

Infusion1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News